Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Therapeutic Approaches for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (All), a Review on Monoclonal Antibodies and Targeted Therapies Publisher Pubmed



Hosseini M1 ; Jafari L1, 2 ; Yami A1 ; Gharehbaghian A1
Authors

Source: Indian Journal of Cancer Published:2022


Abstract

Acute lymphoblastic leukemia (ALL) is the malignant transformation of lymphoid progenitors that affects both children and adults. Although the outcome of pediatric patients has been improved dramatically, there are still many challenges in the treatment of adults. Patients with primary resistant or relapsed disease have the worst outcome and despite the administration of intensified multi-agents chemotherapies, the outcome of this group remains very poor. Accordingly, the development of novel therapeutic options is considered necessary. Having a comprehensive insight into the pathophysiology of ALL and aberrant signaling pathways is crucial for introducing effective targeted therapies. Combination therapies with new drugs and innovative targeted therapies with the aim of affecting the main aberrant signaling pathways in the disease are considered as new approaches. Here we tried to have a comprehensive review on the potential molecular targets in the treatment of refractory/relapsed ALL and the current therapeutic agents. © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
2. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
Experts (# of related papers)
Other Related Docs
14. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
15. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
16. Tumor Immunology, Clinical Immunology (2022)